C the Signs – Clinical decision support tool

C the Signs is an integrated (Systm1 or EMIS) clinical decision support tool to aid cancer diagnosis. It uses AI to support GPs with risk-assessing patients by checking combinations of signs, symptoms, and risk factors, and will then suggesting an appropriate diagnostic pathway.

Improving Cancer Detection in Primary Care with AI: The Impact of C the Signs

C the Signs is an integrated clinical decision-support system that assists healthcare professionals to spot cancer at an earlier stage, when survival rates are highest. The system uses the latest robust  evidence and clinical data to help detect cancer – evaluating tens of thousands of peer-reviewed publications, and only uses data points which have been academically validated.

Late-stage cancer diagnosis significantly impacts patient outcomes and healthcare costs. In the UK, early cancer detection via primary care greatly improves treatment outcomes including survival rates (1).

C the Signs is a validated algorithm that analyses a patient’s electronic medical record (EMIS, SystmOne, Vision) checking for combinations of signs, symptoms, risk factors, clinical markers and other information, to support GPs to make suspected cancer referrals and even suggest an appropriate diagnostic pathway. C the Signs is accessed through a desktop tool bar, with just one click.

By helping GPs identify patients at risk of cancer sooner and reduce unnecessary urgent suspected cancer (USC) referrals, the platform also eases system pressures and releases valuable clinical capacity.

Research presented to the American Society of Oncology, C the Signs demonstrated by a 12.3% increase in cancer detection rates among 35 GP practices (in the East of England) using the tool, covering a population of approx. 420,000 people.

The improvement was achieved without additional healthcare resource use, showcasing efficient early-stage cancer detection (2) (3).

Health Innovation East’s support

Health Innovation East initially supported the implementation of C the Signs across 35 GP practices in Ipswich and East Suffolk.

Across these practices, there were 303 registered users in February 2023, with 60% of users in clinical roles and 40% in administrative roles. Health Innovation East provided funding and project management support for an independent real-world evaluation of the innovation, led by Anglia Ruskin University.

The evaluation found that staff rate the tool as highly effective, easy to use. It is also supportive of clinical decisions -particularly through prompts and suggestions to help them consider lesser-known cancers. The evaluation also highlighted areas for improvement to enable wider adoption and spread of C the Signs, such as an enhancing and extending the onboarding process for staff and implementing peer support between high and low users of the tool. Read the final report.

In a Health Innovation Network survey the company suggested £257K of sales was supported by Health Innovation East’s support 2023/24. Additionally, £292,000 was received from NHS England and Wessex Cancer Alliance, with industry providing £30,000 in-kind for evaluation.

A study, funded by Health Innovation East, enabled C the Signs to conduct a health economic evaluation of the impact of platform in SNEE ICB, which informed the ROI model and cost savings analysis. The study showed a potential 808% return on investment (ROI) for the NHS and associated with 272 patients being diagnosed earlier and £1.5 million in annual cost savings – demonstrating how AI can help improve patient outcomes and optimise NHS resources.

The work was supported by Imperial College London and has been published in the Journal of Clinical Oncology

 

C the Signs first launched in the East of England in 2021, supporting GP practices caring for 100,000 patients. With strong engagement from primary care and invaluable support from Health Innovation East, we’ve been able to significantly expand our reach across the region. C the Signs has played a key role in driving faster, earlier, and more accurate cancer detection in a cost-effective way. Today, we’re supporting over 2 million patients in the East of England and reaching 10 million patients nationally—empowering GP practices to make real strides in early cancer diagnosis and improving patient outcomes.

 

Dr Bea Bakshi, CEO & Co-Founder, C the Signs

C the Signs continues to actively spread and expand throughout the East of England and the rest of the country.

The organisation has graduated from the inaugural cohort of the White House CancerX Accelerator programme.

Visit C the Signs' website

Find out more about C the Signs here

Get in touch

Please get in touch to hear how C the Signs can help your region.

Share your idea

Do you have a great idea that could deliver meaningful change in the real world?

Get involved

Newsletter